What is the recommended approach to evaluating and managing polyarthritis in a pediatric patient?

Approach to Polyarthritis in Pediatrics

In children with active polyarthritis, initiate DMARD therapy (specifically methotrexate) immediately rather than NSAIDs alone, as NSAIDs are insufficient as monotherapy for chronic synovitis and delay disease control. 1

Initial Evaluation

Key Clinical Features to Identify

• Number and pattern of joints involved: Polyarthritis requires ≥5 joints affected over disease course (≥4 joints in some definitions) 2
• Presence of true synovitis: Look for joint swelling, warmth, effusion, and limited range of motion—not just pain
• Duration: Acute (<6 weeks) vs. chronic (>6 weeks) presentation
• Systemic features: Fever patterns, rash, hepatosplenomegaly, lymphadenopathy
• Extra-articular manifestations: Screen for uveitis risk, growth abnormalities 3

Risk Stratification

Identify high-risk features that influence treatment intensity 1:

• Positive anti-CCP antibodies
• Positive rheumatoid factor
• High-risk joint involvement (cervical spine, wrist, hip)
• High disease activity scores
• Physician assessment of high risk for disabling joint damage

Treatment Algorithm

Initial Therapy for All Patients

Strongly recommend starting with DMARD therapy over NSAID monotherapy (moderate evidence) 1

• Methotrexate is the first-line DMARD, conditionally recommended over leflunomide or sulfasalazine 1

  • Greater volume of effectiveness data
  • Better safety profile than sulfasalazine (lower risk of Stevens-Johnson syndrome, bone marrow suppression)
  • Leflunomide lacks dosing/safety data in children <3 years and has no liquid formulation
  • Subcutaneous methotrexate may offer advantages over oral 4

• Methotrexate monotherapy is preferred over triple DMARD therapy initially (low evidence) 1

Role of NSAIDs

NSAIDs are conditionally recommended only as adjunct therapy for symptom management during DMARD/biologic initiation or escalation—never as monotherapy for chronic synovitis 1

Biologic Therapy Considerations

For patients WITHOUT risk factors:

• Start with DMARD monotherapy; reserve biologics for inadequate response 1

For patients WITH risk factors:

• DMARD monotherapy is still conditionally recommended first
• However, initial biologic therapy may be preferred when high-risk joints are involved, disease activity is very high, or physician judges high risk of disabling damage 1

Glucocorticoid Use

• Bridging therapy: Short course (<3 months) conditionally recommended in moderate/high disease activity during DMARD initiation 1
• Strongly recommend AGAINST chronic low-dose glucocorticoids regardless of disease activity 1
• Intraarticular glucocorticoid injections are appropriate for specific joint involvement 1

Subsequent Therapy Based on Disease Activity

Low Disease Activity (cJADAS-10 ≤2.5 with ≥1 active joint)

Conditionally recommend escalating therapy over continuing current regimen 1

Escalation options:

• Intraarticular glucocorticoid injections
• Optimize DMARD dosing
• Trial methotrexate if not yet used
• Add or change biologic

Moderate/High Disease Activity (cJADAS-10 >2.5)

If on DMARD monotherapy:

• Add a biologic to the DMARD rather than switching to a second DMARD or triple DMARD therapy (low evidence) 1

If on first TNF inhibitor (±DMARD) with inadequate response:

• Switch to non-TNFi biologic (tocilizumab or abatacept) over switching to second TNFi (very low evidence) 1
• Exception: Second TNFi may be appropriate if good initial response followed by secondary failure
• Emerging evidence supports JAK inhibitors as options 4

If on second biologic:

• Use TNFi, abatacept, or tocilizumab (depending on prior exposure) over rituximab 1

Biologic-DMARD Combination Therapy

Combination therapy with DMARD is conditionally recommended for etanercept, adalimumab, golimumab, abatacept, and tocilizumab over biologic monotherapy 1

Combination therapy with DMARD is STRONGLY recommended for infliximab (low evidence) 1

Adjunctive Therapies

Physical and occupational therapy are conditionally recommended for patients with or at risk of functional limitations 1

Critical Timing Considerations

• Adequate methotrexate trial = 3 months before declaring failure 1
• However, if minimal/no response at 6-8 weeks, changing or adding therapy may be appropriate 1
• Early aggressive therapy may help achieve inactive disease faster and improve long-term outcomes 5

Common Pitfalls

• Delaying DMARD initiation: NSAIDs alone allow disease progression and joint damage
• Underdosing methotrexate: Ensure adequate trial before declaring failure
• Chronic glucocorticoid use: Strongly contraindicated due to growth/developmental concerns
• Sequential TNFi trials: After first TNFi failure, switching to different mechanism (tocilizumab/abatacept) is preferred
• Missing uveitis screening: Extra-articular complications require monitoring regardless of joint disease control 3

The 2019 ACR/Arthritis Foundation guidelines 1 provide the most comprehensive, evidence-based framework for pediatric polyarthritis management, with recent data 4, 5 supporting earlier aggressive therapy and emerging treatment options.